



Epigenetic Mechanisms Underlying the Dynamic Expression of Cancer-Testis Genes, *PAGE2*, *-2B* and *SPANX-B*, during Mesenchymal-to-Epithelial Transition

Sinem Yilmaz-Ozcan¹, Asli Sade², Baris Kucukkaraduman¹, Yasemin Kaygusuz¹, Kerem Mert Senses¹, Sreeparna Banerjee², Ali Osmay Gure^{1*}

¹ Department of Molecular Biology and Genetics, Bilkent University, Ankara, Turkey, ² Department of Biological Sciences, Middle East Technical University, Ankara, Turkey

Abstract

Cancer-testis (CT) genes are expressed in various cancers but not in normal tissues other than in cells of the germline. Although DNA demethylation of promoter-proximal CpGs of CT genes is linked to their expression in cancer, the mechanisms leading to demethylation are unknown. To elucidate such mechanisms we chose to study the Caco-2 colorectal cancer cell line during the course of its spontaneous differentiation *in vitro*, as we found CT genes, in particular *PAGE2*, *-2B* and *SPANX-B*, to be up-regulated during this process. Differentiation of these cells resulted in a mesenchymal-to-epithelial transition (MET) as evidenced by the gain of epithelial markers CDX2, Claudin-4 and E-cadherin, and a concomitant loss of mesenchymal markers Vimentin, Fibronectin-1 and Transgelin. *PAGE2* and *SPANX-B* up-regulation was accompanied by an increase in Ten-eleven translocation-2 (TET2) expression and cytosine 5-hydroxymethylation as well as the disassociation of heterochromatin protein 1 and the polycomb repressive complex 2 protein EZH2 from promoter-proximal regions of these genes. Reversal of differentiation resulted in down-regulation of *PAGE2*, *-2B* and *SPANX-B*, and induction of epithelial-to-mesenchymal transition (EMT) markers, demonstrating the dynamic nature of CT gene regulation in this model.

Citation: Yilmaz-Ozcan S, Sade A, Kucukkaraduman B, Kaygusuz Y, Senses KM, et al. (2014) Epigenetic Mechanisms Underlying the Dynamic Expression of Cancer-Testis Genes, *PAGE2*, *-2B* and *SPANX-B*, during Mesenchymal-to-Epithelial Transition. PLoS ONE 9(9): e107905. doi:10.1371/journal.pone.0107905

Editor: Keping Xie, The University of Texas MD Anderson Cancer Center, United States of America

Received: May 17, 2014; **Accepted:** August 22, 2014; **Published:** September 17, 2014

Copyright: © 2014 Yilmaz-Ozcan et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Data Availability: The authors confirm that all data underlying the findings are fully available without restriction. All relevant data are within the paper and its Supporting Information files.

Funding: This work was supported by grant nr. 1125023 from The Scientific and Technological Research Council of Turkey (TUBITAK) to AOG, a Young Investigator Award from The Turkish Academy of Sciences to SB, and by TUBITAK-BIDEP fellowships to SYO and BK. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing Interests: The authors have declared that no competing interests exist.

* Email: agure@bilkent.edu.tr

Introduction

Cancer-testis (CT) or cancer-germline genes are expressed in tumors originating from various tissues, as well as in normal germline and trophoblast cells, but are generally silent in other normal tissues of the adult [1–3]. More than 100 different CT genes can be grouped according to homology into families [2]. Despite the lack of sequence similarity between CT genes from different families, re-expression of all CT genes in tumors has been associated with demethylation of CpG residues within their promoter-proximal regions [4]. This shared mechanism of expression regulation is most likely the reason for their coordinate expression in cancer [5–7]. However, the exact mechanism by which DNA demethylation occurs at CT gene promoter-proximal regions in cancers is unknown. CT genes show mostly a heterogeneous expression pattern in tumors [8–10]; in contrast to their expression in testis, which is demarcated and orderly [11]. A study in which stem-like and non-stem like cells of breast cancer were selectively killed, revealed that CT gene expression is generally a feature of more differentiated, non-stem cells [12]. Similarly, in melanoma, a subgroup of cells with more epithelial features express CT genes, when cells with mesenchymal features don't [13]. Interestingly, melanoma cells can switch between these

two classes *in vivo*, suggesting that tumor heterogeneity, as defined by CT gene expression, might represent a transitional phase similar to the switch between epithelial and mesenchymal phenotypes. Indeed, mesenchymal-to-epithelial transition (MET) is associated with the induction of CT gene expression [14]. To define mechanisms involved in regulating CT gene expression in cancer and during MET, we chose to study the Caco-2 spontaneous differentiation model which demonstrates features of MET and EMT during differentiation and de-differentiation, respectively. Our data reveal that the dynamic regulation of the two CT genes, *PAGE2* and *SPANX-B* in this model system, involves alterations of polycomb repressive complex 2 (PRC2) and heterochromatin protein 1 (HP1) occupancy within their promoter-proximal regions, with concordant changes in TET expression and cytosine hydroxymethylation (hmC) levels.

Methods

Cell lines, induction of differentiation and de-differentiation

The Caco-2 cell line was obtained from the SAP Enstitüsü (Ankara, Turkey). HCT116 (colorectal) and Mahlavu (hepatocellular) cancer cell lines were obtained from LGC Standards,




Figure 1. Up-regulation of CT genes in parallel to MET in the Caco-2 SD model. Relative mRNA expression of CT genes (*PAGE2*, *-2B* and *SPANXB*) (A), epithelial genes (*E-cadherin* (*CDH1*), *claudin 4*(*CLDN4*), *CDX2*) (B), and mesenchymal genes (*fibronectin 1* (*FN1*), *vimentin* (*VIM*), *transgelin* (*TAGLN*)) (C) as determined by quantitative PCR at days 0, 10, 20 and 30 post-confluence. Data represent average of two experiments. Change in expression levels for all genes between days 0 and 30 is statistically significant ($P < 0.0001$, by two way ANOVA with Tukey's post hoc test). doi:10.1371/journal.pone.0107905.g001




Figure 2. SPANX-B and vimentin expression are mutually exclusive in differentiating Caco-2 cells. Immunofluorescent staining of differentiating Caco-2 cells with DAPI counterstaining reveals a gradual increase in nuclear SPANX-B (green) with a concomitant decrease in cytoplasmic vimentin expression (red); (20× magnification) (A). Less than 1% of SPANX-B positive cells showed staining for vimentin on day 0 (B). doi:10.1371/journal.pone.0107905.g002




Figure 3. Nuclear co-localization of CDX2 and SPANX-B in differentiating Caco-2 cells. Immunofluorescent staining of differentiating Caco-2 cells with DAPI counterstaining reveals overlapping SPANX-B (Alexa Fluor 488: green) and CDX2 (Alexa Fluor 568: red) expression; (20 \times magnification) (A). More than 60 to 80% of the cells show double-labeling when analyzed quantitatively (B). doi:10.1371/journal.pone.0107905.g003

Middlesex, UK. A lung cancer cell line (SK-LC-17) was from the Memorial Sloan Kettering Cancer Center, NY, USA. Caco-2 cells were grown in EMEM and others in RPMI, supplemented with 20% FBS, 2 mM L-glutamine, 0.1 mM non-essential amino acids, 1.5 g/L sodium bicarbonate and 1 mM sodium pyruvate. All cell culture media and supplements were purchased from Biochrom AG, Berlin, Germany. The first day cells reached confluence was designated day 0. Cells grown in parallel cultures were used to determine phenotypic changes at days 0, 5, 10, 20 and 30, post-confluence. Additional measures of differentiation for cells used in this study have been reported elsewhere [15]. To induce dedifferentiation, cells at the 20th day of differentiation were detached and replated at about 50% confluence and RNA and protein were harvested 5 days following replating.

In silico analysis of CT and EMT gene expression

Expression data contained within GSE1614 [16] was GC-RMA normalized using GeneSpring v. 11.0. CT gene expression was analyzed based on 31 probesets in corresponding to 23 CT genes from 7 families (Figure S2). An interpretation was generated with an entity list composed of EMT related genes as defined by Loboda et al. [17], at three different time points. Genes for validation were selected among those for which significant differences of expression ($p < 0.05$) was observed by one way ANOVA test and Bonferroni FWER correction, when proliferating cells were compared to those at day 15.

Quantitative RT-PCR

Total RNA was isolated using the Trizol reagent (Ambion, Foster City, CA, USA) and treated with DNase I (Ambion, Foster City, CA, USA). 200 ng of RNA was reverse transcribed using Revert-Aid first strand cDNA synthesis kit (Thermo Fisher Scientific, Boston, MA, USA). PCR reactions were performed using an ABI 7500 thermal cycler (Applied Biosystems, Carlsbad, CA, USA). All reactions were performed according to manufacturer's recommendations. TaqMan Gene Expression Assays (Applied Biosystems, Carlsbad, CA, USA) were used for the following: GAPDH (4352934E), SPANX-B (Hs02387419_gH), PAGE2 and -2B (Hs03805505_mH), GAGE (Hs00275620_m1), SSX4 (Hs023441531_m1), NY-ESO-1 (Hs00265824_m1), and MAGE-A3 (Hs00366532_m1). SYBR Green master mix with ROX reference dye (Applied Biosystems, Carlsbad, CA, USA) was used to determine *CDH1*, *CDX2*, *CLDN4*, *VIM*, *FN1* and *TAGLN* expression (Table S1). Cycling conditions for these assays were 50°C for 2 min., 95°C for 10 min., followed by 40 cycles of 94°C for 15 sec., 60–65°C for 1 min. Relative expression was calculated by the $\Delta\Delta C_t$ method [18]. All samples were analyzed in triplicates and all experiments were repeated at least twice.

Promoter methylation analysis

Genomic DNA was isolated by Proteinase K treatment, following a phenol-chloroform extraction protocol. Bisulphite treatment of 200 ng genomic DNA was performed using Zymo DNA Methylation Gold Kit (Zymo Research, Irvine, CA, USA). Bisulphite modified DNA was stored at -20°C and used for PCR within 2 months. Two rounds of DNA amplification were performed using One Taq Hot Start DNA polymerase (New England Bioscience/NEB, Ipswich, MA, USA) using a Perkin Elmer 9700 thermal cycler (Applied Biosystems, Carlsbad, CA, USA). Primers used are given in Table S1. PCR products were gel extracted using the QIAGEN gel extraction kit (Qiagen, Hilden, Germany) and cloned into pCR2.1 (Invitrogen, Carlsbad, CA, USA). Plasmid DNA was purified using the QIAprep Spin Miniprep Kit (Qiagen, Hilden, Germany) from at least ten clones, and sequence analyzed by IONTEK (Istanbul, Turkey).

5-hydroxymethyl cytosine analysis

Caco-2 genomic DNA (gDNA) was sheared by probe sonication (30 sec. on, 30 sec. off, 5 cycles) to obtain 200–600 bp. fragments assessed by 1% agarose gel electrophoretic analysis. Immunoprecipitation was performed using the hMEDIP kit (Abcam, Cambridge, UK) according to manufacturer's instructions. 5 pg of control DNA was spiked into 500 ng of gDNA to use as an internal control. Positive and negative controls of the kit were included in all experiments. 2 μl from the eluted DNA was used as template for quantitative RT-PCR using 2 X SYBR Green master mix with ROX reference dye (Applied Biosystems, Carlsbad, CA,




Figure 4. Bisulfite sequencing of *PAGE2*, *-2B* and *SPANX-B* promoter-proximal regions. Filled and empty circles represent methylated and unmethylated cytosines, respectively. % methylation within each analysed region, based on the 10 clones sequenced is indicated. CpG residues proximal to *PAGE2*, *-2B* and *SPANX-B* promoters during Caco2 differentiation at days 0, 10 and 30 reveals no statistically significant change (by one-way ANOVA). doi:10.1371/journal.pone.0107905.g004

USA) with the primers given in **Tables S1 and S2**. Primer efficiencies were controlled. Cycling conditions were 50°C for 2 min., 95°C for 10 min. followed by 40 cycles of 94°C for 15 sec., 60°C for 1 min. Shared genomic DNA was included in quantitative RT-PCR to calculate % input.

Immunofluorescence microscopy

Cells attached to glass slides by centrifugation using the Shandon CytoSpin3 (Thermo Scientific, Waltham, MA, USA) were immediately fixed in 2% formaldehyde/PBS at room temperature for 15 min. Fixed cells were permeabilized in 0.2% Triton X-PBS for 10 min. followed by blocking with 1% BSA in 0.1% PBS-Tween for 1 hour. Incubations with the primary antibody, diluted at 1:50, were performed overnight at 4°C. Secondary antibody was added at 1:200, following washing in 0.1% PBS-Tween for 5 min. for 3 times, and incubated with cells for 45 min. at room temperature (see **Table S3** for the complete antibody list). Stained samples were mounted with mounting medium (Santa Cruz Biotechnology, Santa Cruz, CA, USA) containing DAPI solution. Cell lines used as positive controls were Mahlavu (*PAGE-2,-2B* and *SPANXB*), MDA-MB 231 (VIM), MCF-7 (TAGLN) and SW620 (CDX2, FN1). Negative controls were combinations of primary antibodies with un-related secondary antibodies. All images were obtained using an AxioCam MRc5 image capture device (Carl Zeiss, Oberkochen, Germany).

Western analysis

Cell lysates (extracted with RIPA buffer) separated on 4–12% Novex Bis-Tris SDS gels (Invitrogen, Carlsbad, CA, USA) were transferred to Immobilon-PSQ membranes (Millipore Corp. Bedford, MA, USA) with an Invitrogen western blotting system (Invitrogen, Carlsbad, CA, USA). Following blocking with 5% milk powder in 0.02% PBS-T, blots were incubated with primary antibody overnight at 4°C. Primary antibody dilutions were 1:1000 for CDX2, fibronectin, vimentin and transgelin, 1:2500 for β -actin and 1:100 for *SPANX-B* and *PAGE-2,-2B* antibodies. HRP conjugated secondary antibody (Abcam, Cambridge, UK) was used at a 1:5000 dilution and incubated at room temperature for 1 hour. Signals were detected using the ECL luminescence assay (BioRad, Hercules, CA, USA).




Figure 5. Increased hydroxymethylation of *PAGE2* and *SPANX-B* during Caco-2 spontaneous differentiation. CHIP experiments using an anti-hmC antibody and primers corresponding to +31 to +182 and +68 to +184 bp from the transcription start site of the *PAGE2* and *SPANX-B* genes, respectively. P values (one-way ANOVA) are 0.001 and 0.07 for *PAGE2* and *SPANX-B*, respectively. doi:10.1371/journal.pone.0107905.g005




Figure 6. TET expression during Caco-2 SD. mRNA of all three TET genes increase gradually during Caco-2 SD (A). An increase in only a 25 kD version (B), but not the full-length TET2 protein (C) occurs simultaneously with the increase in mRNA. BAPTA-AM treatment results in a modest decrease in the 25 kD TET2 protein, with the generation of a larger mw version (D). P values, as determined by one-way ANOVA, are 0.03, 0.01, and 0.07, for Tet1, Tet2, and Tet3, respectively. doi:10.1371/journal.pone.0107905.g006

Chromatin Immunoprecipitation

Chromatin Immunoprecipitation (ChIP) was performed as previously described [15]. Briefly, formaldehyde cross-linked cell constituents were precipitated by protein A sepharose beads coupled to antibodies against EZH2, HP-1 or H3K27m3 (Abcam, Cambridge, UK), as well as isotype-specific control. Precipitated DNA was amplified using primers specific for *PAGE2*, *-2* or *SPANX-B* promoter sequences (Tables S1 and S2), following de-crosslinking.

Results

CT gene expression during Caco-2 spontaneous differentiation (Caco-2 SD)

The undifferentiated colorectal cancer cell line Caco-2 undergoes enterocytic differentiation upon reaching confluence *in vitro* [19,20]. Gradual differentiation has been observed up to 30 days post-confluence as evidenced by the up-regulation of various differentiation-associated genes including sucrase-isomaltase, alkaline phosphatase and carcinoembryonic antigen (CEA), (Figure S1) [15]. An *in silico* analysis of CT gene expression as defined by 31 probesets in the GSE1614 dataset, which contains gene expression data for the Caco-2 SD model obtained during differentiation (proliferating (2nd day), post-proliferation-undifferentiated (8th day), and post-proliferation-differentiated (15th day)) [16], revealed modest up-regulation of almost all CT genes during differentiation (Figure S2). We chose to validate the change in expression of six CT gene/gene families by quantitative RT-PCR in differentiating Caco-2 cells *in vitro*. *GAGE*, *MAGE-A3*, *NY-ESO-1* and *SSX4* transcripts were undetectable on the first day of confluence, as well as at later time points (data not shown). However, significant up-regulation of *PAGE2* (2 and 2B), and *SPANX-B* genes was evident (Figure 1).

PAGE2 and *SPANX-B* expression follow MET in the Caco-2 SD model

Spontaneous differentiation of Caco-2 *in vitro* has been reported to result in MET [21,22]. To determine if this occurred in parallel to the up-regulation of *PAGE2* and *SPANX-B*, we analyzed the GSE1614 dataset for the expression of genes representing EMT in colorectal cancer [17], and selected 6 genes to be validated in our model. Analysis of mRNA and protein expression of these revealed a decrease in mesenchymal genes (*vimentin*, *fibronectin 1* and *transgelin*) with a concomitant increase in expression of epithelial genes (*CDX2*, *claudin-4* and *E-cadherin*) as the cells differentiated, demonstrating that the increase in CT gene expression occurs simultaneously with MET in this model (Figure 1 & Figure S3).

PAGE2, *SPANX-B* and EMT gene expression *in situ*

To study if the changes in protein expression of CT and EMT genes occurred simultaneously in the same cells, we performed double immunofluorescence staining during differentiation. A gradual loss of mesenchymal markers was observed as cells differentiated, with a concomitant increase in epithelial genes and CT genes. *SPANX-B* and *PAGE-2* were frequently co-expressed with the epithelial marker *CDX2* in the same cells but almost never with *VIM* or *FN1* (Figures 2, 3 and Figures S4, S5, S6, S7).

PAGE2 and *SPANX-B* expression correlates with increased hmC and ten-eleven translocation methylcytosine dioxygenase (TET) up-regulation

Expression of all CT genes studied thus far including *PAGE2* and *SPANX-B* have been associated with the demethylation of CpG residues within regions proximal to the transcription start site [1,2,23–26]. In this line, both *PAGE2* and *SPANX-B* can be up-regulated by 5-aza 2'-deoxycytidine treatment (Figure S8).




Figure 7. Overlapping TET2 and CT gene expression in differentiating Caco-2 cells. Double immunofluorescence staining for TET2 (Alexafluor 568: red) and SPANX-B or PAGE2 (Alexafluor 488: green) with DAPI counterstaining 20 days post-confluence show overlapping nuclear expression Magnification: 40× (**A**). More than 95% of cells expressing PAGE2 or SPANX-B were also positive for TET2 staining (**B**). doi:10.1371/journal.pone.0107905.g007

However, bisulfite sequencing of promoter-proximal regions of both *PAGE2* and *SPANX-B* revealed no differences at different stages of Caco-2 SD (**Figure 4**). As bisulfite sequencing is unable to distinguish methyl cytosine (mC) from hmC, we asked whether the change in CT gene expression could be related to altered hmC/mC ratios within their promoters. In fact, chromatin immunoprecipitation (ChIP) with a hmC specific antibody revealed an increase in hmC during differentiation in both *PAGE2* and *SPANX-B2* promoters (**Figure 5**). We next asked if the increase in hmC was related to an increase in TET1, -2, and -3 expression as these proteins are responsible for converting mC to hmC [27,28]. Indeed, the increase in hmC of *PAGE2* and *SPANX-B2* promoters were correlated with an up-regulation of *TET2* mRNA expression, together with modest increases in *TET1* and *3* (**Figure 6A**). Double immunofluorescence staining revealed

that the majority of cells expressing PAGE2 or SPANX-B were positive for TET2 staining; indicating these two events occurred in the same cells (**Figure 7**). It is therefore, likely that the increase in TET2 expression causes increased hmC in these genes. Interestingly, only a low molecular weight translation product (~25 kD) of TET2 was increased in the differentiating cells, when no clear difference in levels of the full-length TET2 protein was observed (**Figure 6B & C**). The peptide used for generating the commercial TET2 antibodies could specifically inhibit recognition of the 25 kD product confirming its identity with TET2 (data not shown). TET2 has recently been shown to undergo proteolytic cleavage by calpain 1 and 2, generating a 25 kD product *in vitro* [29]. To test if a cation-dependent protease is responsible for the generation of the 25 kD protein, we treated differentiating cells with an intracellular Ca²⁺ chelator (BAPTA-AM). This resulted in




Figure 8. Chromatin modifications within *PAGE2* and *SPANX-B* during Caco-2 differentiation. CHIP analysis of *PAGE2*, *-2B* and *SPANX-B* transcription-start site-proximal regions reveals decreased EZH2 occupancy and H3K27m3 (A), as well as decreased HP-1 binding during differentiation (B). P values (one-way ANOVA) calculated for *PAGE2B*, *PAGE2*, and *SPANX-B*, are <0.001, 0.02, and 0.001 for EZH2; 0.003, <0.001, and <0.0001 for H3K27m3; and 0.001, <0.001, and <0.001, for HP1, respectively. doi:10.1371/journal.pone.0107905.g008

a modest reduction in the 25 kD TET2 protein with the concomitant generation of a larger molecular weight product (~50 kD), suggesting that the 25 kD TET2 protein is a Ca⁺² dependent protease cleavage product with a 50 kD intermediate (Figure 6D).

EZH2 and HP-1 occupancy of *PAGE2* and *SPANX-B* promoter proximal regions decrease during differentiation

Hydroxymethylation has been reported to prevail in promoters with dual H3K4 and H3K27 trimethylation that also bind PRC2 proteins [30]. The PRC2 complex protein EZH2 has been implied

in the repression of *GAGE*, another CT gene [31]. We therefore, asked whether increased hmC within CT gene promoters resulted in altered EZH2 binding to the same sites. Indeed, ChIP experiments demonstrated a decrease in EZH2 occupancy, as well as a decrease in H3K27m3 in both *PAGE2* and *SPANX-B* promoters during Caco-2 SD (Figure 8). The PRC2 component SUZ12 has been reported to regulate H3K9 methylation and in turn, heterochromatin protein 1 (HP1 α) binding. In fact, we observed a simultaneous decrease in HP1 binding to both *PAGE2* and *SPANX-B* promoters during differentiation, that correlated with *PAGE2* and *SPANX-B* upregulation (Figure 8). Thus, our data suggest that both PRC2 and HP-1 contribute to maintaining *PAGE2* and *SPANX-B* in a transcriptionally silent state when the




Figure 9. De-differentiation induced EMT and down-regulation of CT and TET genes. De-differentiation induced by growth under non-confluent conditions indicated by decreased *sucrose isomaltase* (SI) mRNA levels (A), leads to down-regulation of *CDX2*, *PAGE2*, *-2B* and *SPANX-B*, with concomitant up-regulation of *TGLN* (B). *TET1* and *-2* mRNAs are also down-regulated during de-differentiation (C). doi:10.1371/journal.pone.0107905.g009

cells have a mesenchymal phenotype, and that increased TET2 expression and hmC mediated transcriptional activation are related to PRC2 and HP-1 dissociation from the promoters of these CT genes during differentiation.

PAGE2 and SPANX-B up-regulation is reversed during EMT

We hypothesized that if the epigenetic alterations underlying CT gene expression happened in parallel to MET, that this process could be reversed if cells entered EMT. To test this hypothesis, differentiated Caco-2 cells were detached and allowed to proliferate for 5 days. This resulted in their rapid de-differentiation as evidenced by down-regulation of SI. De-differentiated cells down-regulated *PAGE2* and *SPANX-B*, as well as *CDX*, as they up-regulated *TAGLN*, in line with ongoing EMT (Figure 9). Although transcription of all three *TET* genes decreased during de-differentiation (Figure 9), we did not observe a decrease in hmC during this period (data not shown). We, therefore, conclude that the up-regulation of CT gene expression is reversible in this model.

Discussion

Previous studies revealed that CT gene expression correlated with an epithelial rather than a mesenchymal phenotype, and showed the up-regulation of CT genes during MET [12,14]. To our knowledge, this is the first report describing alterations in several epigenetic mechanisms within promoters of two CT genes during MET-like differentiation concordant with a dynamic change in gene expression. As bisulfite sequencing of *PAGE2* and *SPANX-B* promoters revealed no change upon differentiation, the increased hmC must strictly involve methylated CpG residues. This is in line with the fact that TET enzymes are responsible for the conversion of 5-methyl cytosine to 5-hydroxymethyl cytosine [27,28]. Conversion of hmC to mC is a far more complex process and might not happen with similar kinetics [32,33]. This is likely the reason why we did not observe a change in hmC during the 5 day de-differentiation process of Caco-2 cells despite the decrease observed in global TET levels. Our finding that *PAGE2*, *SPANX-B* and *TET2* induction is reversible is similar to another study in embryonic stem cells where Vitamin C was shown to induce TET2 expression, which in turn, resulted in up-regulation of CT genes. Both events were reversible upon Vitamin C withdrawal [34].

Although hydroxymethylation within gene promoters has been reported to decrease during differentiation of normal cells, a recent study revealed that about 20% of all modified cytosines in most CT genes in human brain, where they are not expressed, consist of hmC [35]. Up-regulation of TET2 expression in cancer has been associated with MET [36,37]; and therefore, a more differentiated state [30]. Similar to the inverse correlation between EZH2 and CT/TET2 expression we report here, others have shown EZH2 and TET enzymes to repress and induce differentiation of neuronal precursors, respectively [38]. CT genes are up-regulated during the initial stages of development in the human embryo, but decrease as tissues differentiate further [39]. As adult colon tissue does not show *PAGE2* or *SPANX-B* expression (data not shown), had Caco-2 cells the capability of differentiating further, both genes might have been down-regulated completely. On the other hand, the fact that we could not demonstrate up-regulation of *GAGE*, *MAGE-A3*, *NY-ESO-1* or *SSX4* expression in this model might be because these genes are expressed at earlier stages of differentiation. We believe this because *SPANX-B* expression is primarily in post-meiotic cells of the testis (i.e. spermatocytes,

spermatids, or sperm), whereas *GAGE*, *MAGE-A3*, *NY-ESO-1* or *SSX* expression is primarily in spermatogonia [11].

Our data and that of several others' indicate that cancer cells that express CT genes have more of an epithelial rather than a mesenchymal phenotype. We suggest that CT genes *PAGE2* and *SPANX-B* are induced during a window of differentiation that correlates with up-regulation of epithelial markers of differentiation. The Caco-2 SD model has made it possible to observe the actively changing epigenetic landscape within the promoters of these CT genes. However, as CT gene expression in tumors has closely been related to the methylation state of their promoter, the process that leads to CT gene induction *in vivo* might ultimately result in "fixing" of the epigenetic state which would in turn result in CpG methylation. Yet, via dynamic MET in tumors [40], it is conceivable that even this might change over the course of the disease.

From a clinical perspective, data from our lab as well as from others reveal that sub-grouping of tumors based on gene expression profiles can clearly identify cells with different chemosensitivity profiles [12,41,42]. In this line, we predict future studies will reveal distinct drug sensitivity profiles for colorectal cancer subtypes as possibly defined by *PAGE2* and *SPANX-B* expression, for which the Caco-2 SD model could be used.

Supporting Information

Figure S1 Post-confluence differentiation of Caco-2 *in vitro*. Up-regulation of *sucrase-isomaltase* (A), and carcinoembryonic antigen (CEA) (B) in cells collected at indicated days post confluence (DPC) as determined by quantitative RT-PCR, and Western analysis, respectively. Alkaline phosphatase expression is also upregulated as determined by immunohistochemistry revealing differentiation (C). Other measures of differentiation for the cells used in this study have been reported previously (ref. 17). *P<0.001 (ANOVA with Tukey's post hoc test). (DOCX)

Figure S2 Up-regulation of CT gene expression during Caco-2 spontaneous differentiation *in vitro*. Heat map based on 31 probesets in GSE1614 corresponding to 23 CT genes from 7 families. As compared to proliferating cells, gene expression incrementally increases in at confluence (8th day) and further during post-confluence differentiation (15th day). (DOCX)

Figure S3 Western analysis of differentially expressed genes during Caco-2 SD. A gradual increase in *SPANX-B* and *CDX2* in parallel to a decrease in expression of *FN*, *VIM* and *TGLN* up to day 30 post-confluence. Results from 3 independent differentiation experiments are shown. (DOCX)

Figure S4 *SPANX-B* and Fibronectin expression show limited overlap in differentiating Caco-2 cells. Immunofluorescent staining of differentiating Caco-2 cells with DAPI counterstaining reveals a gradual increase in nuclear *SPANX-B* (Alexa Fluor 488: green) with a concomitant decrease in cytoplasmic fibronectin expression (Alexa Fluor 568: red); (20× magnification) (A). Less than 10% of cells expressing *SPANX-B* stained for fibronectin at day 0 (B). (DOCX)

Figure S5 *PAGE2*, -2B and Vimentin expression are mutually exclusive in differentiating Caco-2 cells. Immunofluorescent staining of differentiating Caco-2 cells with DAPI counterstaining reveals a gradual increase in nuclear *PAGE2*, -2B (Alexa Fluor 488: green) with a concomitant decrease in

cytoplasmic vimentin expression (Alexa Fluor 568: red); (20× magnification) (A). Less than 10% of cells showed double fluorescence when staining was analyzed quantitatively at day 0. At later time points, none of the cells showed double staining (B). (DOCX)

Figure S6 PAGE2, -2B and fibronectin expression are mutually exclusive in differentiating Caco-2 cells. Immunofluorescent staining of differentiating Caco-2 cells with DAPI counterstaining reveals a gradual increase in nuclear PAGE2, -2B (Alexa Fluor 488: green) with a concomitant decrease in cytoplasmic fibronectin expression (Alexa Fluor 568: red); (20× magnification) (A). Less than 15% of cells showed double fluorescence when staining was analyzed quantitatively at day 0 (B). (DOCX)

Figure S7 Nuclear co-localization of CDX2 and PAGE2, -2B in differentiating Caco-2 cells. Immunofluorescent staining of differentiating Caco-2 cells with DAPI counterstaining reveals overlapping PAGE2, -2B (Alexa Fluor 488: green) and CDX2 (Alexa Fluor 568: red) expression; (20× magnification) (A). More than 80% of the cells show double-labeling when analyzed quantitatively (B). (DOCX)

Figure S8 Induction of PAGE2,-2B and SPANX-B gene expression by 5-aza-2'-deoxycytidine in HCT116 (top)

References

- Scanlan MJ, Gure AO, Jungbluth AA, Old LJ, Chen YT (2002) Cancer/testis antigens: an expanding family of targets for cancer immunotherapy. *Immunological Reviews* 188: 22–32.
- Caballero OL, Chen YT (2009) Cancer/testis (CT) antigens: potential targets for immunotherapy. *Cancer Sci* 100: 2014–2021.
- Hofmann O, Caballero OL, Stevenson BJ, Chen YT, Cohen T, et al. (2008) Genome-wide analysis of cancer/testis gene expression. *Proceedings of the National Academy of Sciences of the United States of America* 105: 20422–20427.
- Loriot A, Reister S, Parvizi GK, Lysy PA, De Smet C (2009) DNA methylation-associated repression of cancer-germline genes in human embryonic and adult stem cells. *Stem Cells* 27: 822–824.
- Mashino K, Sadanaga N, Tanaka F, Yamaguchi H, Nagashima H, et al. (2001) Expression of multiple cancer-testis antigen genes in gastrointestinal and breast carcinomas. *Br J Cancer* 85: 713–720.
- Gure AO, Chua R, Williamson B, Gonen M, Ferreira CA, et al. (2005) Cancer-testis genes are coordinately expressed and are markers of poor outcome in non-small cell lung cancer. *Clinical Cancer Research* 11: 8055–8062.
- Woloszynska-Read A, Mhawech-Fauceglia P, Yu JH, Odunsi K, Karpf AR (2008) Intertumor and intratumor NY-ESO-1 expression heterogeneity is associated with promoter-specific and global DNA methylation status in ovarian cancer. *Clinical Cancer Research* 14: 3283–3290.
- Jungbluth AA, Busam KJ, Kolb D, Iversen K, Coplan K, et al. (2000) Expression of MAGE-antigens in normal tissues and cancer. *Int J Cancer* 85: 460–465.
- Jungbluth AA, Chen YT, Busam KJ, Coplan K, Kolb D, et al. (2002) CT7 (MAGE-C1) antigen expression in normal and neoplastic tissues. *Int J Cancer* 99: 839–845.
- Jungbluth AA, Stockert E, Chen YT, Kolb D, Iversen K, et al. (2000) Monoclonal antibody MA454 reveals a heterogeneous expression pattern of MAGE-1 antigen in formalin-fixed paraffin embedded lung tumours. *Br J Cancer* 83: 493–497.
- Chen YT, Chiu RT, Lee P, Beneck D, Jin BQ, et al. (2011) Chromosome X-encoded cancer/testis antigens show distinctive expression patterns in developing gonads and in testicular seminoma. *Human Reproduction* 26: 3232–3243.
- Gupta PB, Onder TT, Jiang G, Tao K, Kuperwasser C, et al. (2009) Identification of selective inhibitors of cancer stem cells by high-throughput screening. *Cell* 138: 645–659.
- Hoek KS (2007) DNA microarray analyses of melanoma gene expression: a decade in the mines. *Pigment Cell Res* 20: 466–484.
- Argast GM, Krueger JS, Thomson S, Sujka-Kwok I, Carey K, et al. (2011) Inducible expression of TGF beta, Snail and Zeb1 recapitulates EMT in vitro and in vivo in a NSCLC model. *Clinical & Experimental Metastasis* 28: 593–614.
- Astarci E, Sade A, Cimen I, Savas B, Banerjee S (2012) The NF-kappaB target genes ICAM-1 and VCAM-1 are differentially regulated during spontaneous differentiation of Caco-2 cells. *FEBS J* 279: 2966–2986.
- Fleet JC, Wang L, Vitek O, Craig BA, Edenberg HJ (2003) Gene expression profiling of Caco-2 BBe cells suggests a role for specific signaling pathways during intestinal differentiation. *Physiol Genomics* 13: 57–68.
- Loboda A, Nebozhyn MV, Watters JW, Buser CA, Shaw PM, et al. (2011) EMT is the dominant program in human colon cancer. *BMC Medical Genomics* 4.
- Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2^{-Delta Delta C(T)} Method. *Methods* 25: 402–408.
- Pinto M, Robineleon S, Appay MD, Kedinger M, Triadou N, et al. (1983) Enterocyte-Like Differentiation and Polarization of the Human-Colon Carcinoma Cell-Line Caco-2 in Culture. *Biology of the Cell* 47: 323–330.
- Simon-Assmann P, Turck N, Sidhoum-Jenny M, Gradwohl G, Kedinger M (2007) In vitro models of intestinal epithelial cell differentiation. *Cell Biology and Toxicology* 23: 241–256.
- Halbleib JM, Saaf AM, Brown PO, Nelson WJ (2007) Transcriptional modulation of genes encoding structural characteristics of differentiating Enterocytes during development of a polarized epithelium in vitro. *Molecular Biology of the Cell* 18: 4261–4278.
- Saaf AM, Halbleib JM, Chen X, Yuen ST, Leung SY, et al. (2007) Parallels between global transcriptional programs of polarizing Caco-2 intestinal epithelial cells in vitro and gene expression programs in normal colon and colon cancer. *Mol Biol Cell* 18: 4245–4260.
- Fratta E, Coral S, Covre A, Parisi G, Colizzi F, et al. (2011) The biology of cancer testis antigens: putative function, regulation and therapeutic potential. *Mol Oncol* 5: 164–182.
- Cannuyer J, Loriot A, Parvizi GK, De Smet C (2013) Epigenetic Hierarchy within the MAGEA1 Cancer-Germline Gene: Promoter DNA Methylation Dictates Local Histone Modifications. *Plos One* 8.
- Wang ZQ, Zhang J, Zhang YN, Lim SH (2006) SPAN-Xb expression in myeloma cells is dependent on promoter hypomethylation and can be upregulated pharmacologically. *International Journal of Cancer* 118: 1436–1444.
- Wang ZQ, Zhang J, Zhang Y, Srivenugopal K, Lim SH (2006) SPAN-XB core promoter sequence is regulated in myeloma cells by specific CpG dinucleotides associated with MeCP2 protein. *Blood* 108: 628a–628a.
- Iyer LM, Tahiliani M, Rao A, Aravind L (2009) Prediction of novel families of enzymes involved in oxidative and other complex modifications of bases in nucleic acids. *Cell Cycle* 8: 1698–1710.
- Loenarz C, Schofield CJ (2009) Oxygenase catalyzed 5-methylcytosine hydroxylation. *Chem Biol* 16: 580–583.
- Wang Y, Zhang Y (2014) Regulation of TET Protein Stability by Calpains. *Cell Rep* 6: 278–284.

30. Jiang Y, Liu S, Chen X, Cao Y, Tao Y (2013) Genome-wide distribution of DNA methylation and DNA demethylation and related chromatin regulators in cancer. *Biochim Biophys Acta* 1835: 155–163.
31. Sun F, Chan E, Wu Z, Yang X, Marquez VE, et al. (2009) Combinatorial pharmacologic approaches target EZH2-mediated gene repression in breast cancer cells. *Mol Cancer Ther* 8: 3191–3202.
32. Tsukada Y (2012) Hydroxylation mediates chromatin demethylation. *J Biochem* 151: 229–246.
33. Solary E, Bernard OA, Tefferi A, Fuks F, Vainchenker W (2014) The Ten-Eleven Translocation-2 (TET2) gene in hematopoiesis and hematopoietic diseases. *Leukemia* 28: 485–496.
34. Blaschke K, Ebata KT, Karimi MM, Zepeda-Martinez JA, Goyal P, et al. (2013) Vitamin C induces Tet-dependent DNA demethylation and a blastocyst-like state in ES cells. *Nature* 500: 222–226.
35. Wen L, Li X, Yan L, Tan Y, Li R, et al. (2014) Whole-genome analysis of 5-hydroxymethylcytosine and 5-methylcytosine at base resolution in the human brain. *Genome Biol* 15: R49.
36. Ficiz G, Branco MR, Seisenberger S, Santos F, Krueger F, et al. (2011) Dynamic regulation of 5-hydroxymethylcytosine in mouse ES cells and during differentiation. *Nature* 473: 398–402.
37. Song SJ, Polisenio L, Song MS, Ala U, Webster K, et al. (2013) MicroRNA-antagonism regulates breast cancer stemness and metastasis via TET-family-dependent chromatin remodeling. *Cell* 154: 311–324.
38. Hahn MA, Qiu R, Wu X, Li AX, Zhang H, et al. (2013) Dynamics of 5-hydroxymethylcytosine and chromatin marks in Mammalian neurogenesis. *Cell Rep* 3: 291–300.
39. Gjerstorff MF, Harkness L, Kassem M, Frandsen U, Nielsen O, et al. (2008) Distinct GAGE and MAGE-A expression during early human development indicate specific roles in lineage differentiation. *Hum Reprod* 23: 2194–2201.
40. Yao D, Dai C, Peng S (2011) Mechanism of the mesenchymal-epithelial transition and its relationship with metastatic tumor formation. *Mol Cancer Res* 9: 1608–1620.
41. Isbilen M, Senses KM, Gure AO (2013) Predicting Chemotherapy Sensitivity Profiles for Breast Cancer Cell Lines with and Without Stem Cell-Like Features. *Curr Signal Transduct Ther* 8: 268–273.
42. Isbilen M, Gure AO (2014) Identifying effective molecularly targeted drugs for hematological cancers. *Turkiye Klinikleri J Hematol-SpecialTopics* 7: 1–7.